SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Dec 22, 2010

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Dec. 22, 2010 · CIK: 0000894158 · Accession: 0001144204-10-067943

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-12584

Date

December 31, 2010

Author

/s/

Form

CORRESP

Company

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

VIA EDGAR AND United States Securities Attention: Adeona Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2010 Form 10-Q for the interim period ended June 30, 2010 File No. 001-12584

Dear Mr. Rosenberg:

We acknowledge that the adequacy and accuracy of the disclosure in our filings is our responsibility. We acknowledge that the staff comments or changes to disclosure do not foreclose the Commission from taking any action with respect to the filings. We acknowledge that the company may not assert staff comments as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,
/s/
James
S. Kuo

Show Raw Text

CORRESP
1
filename1.htm

    Unassociated Document

                  December 17,
    2010

          VIA
EDGAR AND

    OVERNIGHT
MAIL

    United
States Securities

       and
Exchange Commission

    100 F
Street, NE

    Mail Stop
4270

    Washington,
D.C.  20549

              Attention:

              Jim
      Rosenberg

              Senior Assistant Chief
    Accountant

              Re:

              Adeona
      Pharmaceuticals, Inc.

                Form
      10-K for the year ended December 31, 2010

                Form
      10-Q for the interim period ended June 30, 2010

                File No.
      001-12584

    Dear Mr.
Rosenberg:

    We
acknowledge that the adequacy and accuracy of the disclosure in our filings is
our responsibility.  We acknowledge that the staff comments or changes
to disclosure do not foreclose the Commission from taking any action with
respect to the filings.  We acknowledge that the company may not
assert staff comments as a defense in any proceedings initiated by the
Commission or any person under the federal securities laws of the United
States.

                    Sincerely,

                    /s/
      James
      S. Kuo

                    James
      S. Kuo

SecProbe.io